Study of etentamig and a CELMoD drug for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma that has returned or is not responding to your last treatment.
- You need to be well enough to be up and about at least half of the day (ECOG score 0 or 1).
- Your disease must be measurable by a central lab test.
- You cannot have had etentamig before.
- You cannot have had a BCMA-targeted therapy before.
- You cannot have had a CELMoD drug called iberdomide or mezigdomide before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
This trial tests a combination of two drugs, mezigdomide (a pill) and elranatamab (an injection), for people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find the best dose and see if the combination is safe and effective.
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
This trial tests a new combination of two drugs, elranatamab and iberdomide, for people whose multiple myeloma has returned or stopped responding to previous treatments. The goal is to see if this combination can help control the disease.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.